Upstream Processing

Cell-free Expression Systems Offer Alternatives

Cell-free expression shows promise in preclinical applications but presents scale-up challenges.

Recombinant Supplements Offer Lower Contamination Risk

Demand for recombinant microorganism-based cell culture supplements.

Maximum Output Starts with Optimized Upstream Processing

April 02, 2021

Biopharmaceutical companies and contract manufacturers respond to changing demand dynamics for upstream bioprocessing capacity.

Single-Use Bags Help Maintain Aseptic Ingredient Transfer to Bioreactors

April 02, 2021

The innovation of single-use technologies is applicable early on in the manufacturing process.

Jumping Seed Train Intensification Hurdles to Maximize Yield

March 02, 2021

Overcoming time and cost constraints can help enable seed train intensification efforts to maximize product yield.

Remote Monitoring and Big Data Advance Upstream Automation

February 02, 2021

Connected, integrated bioprocessing enterprises with greater data analytics capabilities are coming.

Cultivating a Synthetic Biology-Based Approach to Improving Cell Culture

January 02, 2021

Cell-culture optimization may see benefits from a synthetic biology-based approach that improves product titer, quality, and time.

Using Automated Inline Dilution to Ease Bottlenecking

December 02, 2020

Establishing an automated inline dilution system can potentially ease bottlenecking delays resulting from higher upstream yields.

Control Strategies for Perfusion Cell Culture

November 02, 2020

PAT advances are enabling improved process understanding, process control, and error prevention.

Synthetic Biology Offers a Solution to Cell Therapy Source Material Constraints

October 02, 2020

An innovation such as synthetic biology can develop a consistently stable starting cell line for cell therapy source material.

Current Challenges with Cell Culture Scale-up for Biologics Production

October 02, 2020

Bioreactor technology advances can offer seamless manufacturing scale-up and can reduce the timeline and cost of biologics production.

Commercial Production of Gene Therapies Using Suspension or Adherent Cell Lines

September 03, 2020

This article will explore the traditional path from the laboratory to the clinic and how the fixed-bed technology provides an alternative solution to meet commercial demands.